VEEV

VEEV

USD

Veeva Systems Inc. Class A Common Stock

$282.160-7.840 (-2.703%)

实时价格

Healthcare
Health Information Services
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$290.000

最高价

$291.690

最低价

$278.260

成交量

1.27M

公司基本面

市值

46.1B

所属行业

Health Information Services

国家/地区

United States

交易统计

平均成交量

1.43M

交易所

NYQ

货币

USD

52周价格范围

最低价 $176.41当前价 $282.160最高价 $291.69

AI分析报告

最后更新: 2025年6月12日
由AI生成数据来源: Yahoo Finance, Bloomberg, SEC

VEEV: Veeva Systems Inc. Class A Common Stock – Unpacking Recent Trends & Future Possibilities

Stock Symbol: VEEV Generate Date: 2025-06-12 02:08:35

Let's break down what's been happening with Veeva Systems and what the data might be telling us.

The Latest Buzz: News Sentiment

The news flow around Veeva has been overwhelmingly positive lately. We're seeing multiple announcements about major wins and strategic moves. For instance, over 50 medtech companies, including big names, are now using Veeva MedTech for clinical trials. That's a huge vote of confidence.

Then there's the report showing 88% of medtech firms are prioritizing postmarket quality modernization, a space where Veeva clearly plays a big role. Plus, they've teamed up with Sarah Cannon Research Institute for oncology trials and secured Astellas as a global standard for their CRM. These aren't small deals; they show Veeva is deepening its roots with key players in the life sciences and healthcare sectors.

Even analyst firms like Mizuho and Needham are jumping in, raising their price targets for VEEV. This kind of consistent positive news, especially with big client wins and industry trends aligning, creates a strong sense of optimism around the company.

Price Check: What the Stock Chart Says

Looking at the last 30 days, Veeva's stock (VEEV) has seen some interesting moves. Back in mid-March, it was hovering around the $230-$240 range. Things got a bit choppy in early April, dipping below $220, but then it started a steady climb.

The real action happened around May 29th. After announcing fiscal Q1 2026 results, the stock saw a significant jump, breaking out of its previous range. It went from the mid-$230s to well over $270, even touching close to $290. This kind of sharp upward movement, especially on earnings news, often indicates strong investor reaction.

Currently, the stock is trading around $288.55 (as of June 11th's close). This puts it near its 52-week high of $291.68, which is a strong position. The average daily volume has also picked up, especially during that late May surge, showing increased interest.

Now, what about the future? AIPredictStock.com's AI model suggests a positive lean. It predicts a slight movement today (0.00%), followed by a 1.55% increase tomorrow, and a more substantial 4.04% jump the day after. This aligns with the recent upward trend and the positive news.

Putting It All Together: Outlook & Strategy Ideas

Given the strong positive news sentiment, the recent significant upward price movement, and the AI's predictions for continued gains, the near-term leaning for VEEV appears to be quite positive. It seems to favor potential buyers, suggesting a possible 'accumulate' window, especially if there's any minor pullback.

Potential Entry Consideration: If you're thinking about VEEV, the current price area, around $283.92 to $284.95, could be interesting. Why? The AI model highlights the current price being very close to a support level ($283.87), which often acts as a floor, suggesting a potential buying opportunity. The overall positive momentum from news and analyst upgrades also supports this.

Potential Exit/Stop-Loss Consideration: For managing risk, a stop-loss around $255.77 might be considered. This level is well below recent significant lows and would help protect against a sharp reversal if the positive trend doesn't hold. On the upside, if the stock continues its climb as predicted, a take-profit target around $301.61 could be a point to watch, aligning with the AI's projected upward trend and analyst targets.

Company Context

It's important to remember that Veeva Systems operates squarely in the "Health Information Services" sector, providing cloud-based software specifically for the global life sciences industry. This means their success is deeply tied to the ongoing digital transformation and regulatory needs of pharmaceutical, biotech, and medtech companies. The recent news about clinical trials, postmarket quality, and CRM adoption directly reflects their core business and its growth drivers. Their P/E ratio is on the higher side at 42.68, which is common for growth companies in specialized tech sectors, but it's something to keep in mind.


Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Investing in stocks involves risks, and past performance is not indicative of future results. Always conduct your own thorough research and consult with a qualified financial professional before making any investment decisions.

相关新闻

PR Newswire

Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech

Veeva Systems (NYSE: VEEV) today announced that more than 50 medtech companies, including 11 of the top 20 medtechs and seven of the top 10 medtech...

查看更多
Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech
PR Newswire

Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech

Veeva Systems (NYSE: VEEV) today announced that more than 50 medtech companies, including 11 of the top 20 medtechs and seven of the top 10 medtech...

查看更多
Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech
PR Newswire

New Study Finds 88% of Medtechs Prioritizing Postmarket Quality Modernization Within Next 3 Years

The 2025 Veeva MedTech Postmarket Quality Benchmark Report reveals that 88% of the medtech companies surveyed are advancing postmarket quality...

查看更多
New Study Finds 88% of Medtechs Prioritizing Postmarket Quality Modernization Within Next 3 Years
PR Newswire

New Study Finds 88% of Medtechs Prioritizing Postmarket Quality Modernization Within Next 3 Years

The 2025 Veeva MedTech Postmarket Quality Benchmark Report reveals that 88% of the medtech companies surveyed are advancing postmarket quality...

查看更多
New Study Finds 88% of Medtechs Prioritizing Postmarket Quality Modernization Within Next 3 Years
PR Newswire

Veeva and Sarah Cannon Research Institute Form Strategic Collaboration to Advance Oncology Clinical Trials

Veeva Systems (NYSE: VEEV) and Sarah Cannon Research Institute (SCRI) today announced a strategic collaboration to drive speed and efficiency in...

查看更多
Veeva and Sarah Cannon Research Institute Form Strategic Collaboration to Advance Oncology Clinical Trials
PR Newswire

Astellas Chooses Veeva Vault CRM as Global Standard

Veeva Systems (NYSE: VEEV) today announced Astellas has chosen Veeva Vault CRM globally and Veeva China CRM for China. "At Astellas, we discover and...

PR Newswire

Astellas Chooses Veeva Vault CRM as Global Standard

Veeva Systems (NYSE: VEEV) today announced Astellas has chosen Veeva Vault CRM globally and Veeva China CRM for China. "At Astellas, we discover and...

AI预测Beta

AI建议

看涨

更新于: 2025年6月13日 01:09

看跌中性看涨

61.7% 置信度

风险与交易

风险等级1/5
低风险
适合于
保守
交易指南

入场点

$283.92

止盈点

$301.61

止损点

$255.77

关键因素

PDI 4.1高于MDI 3.8,且ADX 8.5,表明看涨趋势
当前价格正在接近支撑水平$283.87,值得关注
交易量是平均值的6.3倍(21,268),表明极强的买入压力
MACD -0.0709低于信号线-0.0203,表明看跌交叉

保持更新

设置价格提醒,获取AI分析更新和实时市场新闻。